NEW YORK, March 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the upcoming 36th Annual Cowen & Company Global Healthcare Conference, and the 28th Annual ROTH Conference.
|36th Annual Cowen & Company Global Healthcare Conference|
|Date:||Monday, March 7|
|Time:||3:20pm Eastern Time|
|Location:||Salon C, Boston Marriott Copley Place, Boston, MA|
|28th Annual ROTH Conference|
|Date:||Tuesday, March 15|
|Time:||3:00pm Pacific Time|
|Location:||Salon 2 Blue, The Ritz Carlton Hotel, Dana Point|
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. LifeSci Advisors, LLC Investor Relations Michael Wood 888-388-2327 646-597-6983 firstname.lastname@example.org email@example.com